Loading
A phase 3 trial of Pamidronate in Multiple myeloma, run by Nordic Myeloma Study Group, completed.
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month is a phase 3 interventional study registered as NCT00376883 by Nordic Myeloma Study Group, with 500 participants recorded, started 2000-01. Interventions recorded: pamidronate. Conditions recorded: Multiple Myeloma.
Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Shares Pamidronate, Multiple myeloma and the tag pipeline.
Shares Pamidronate, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.